Company expands precision medicine solutions for drug development and clinical utility programs.
LAUSANNE, SWITZERLAND – August 31, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced election of Dr. Miro Venturi to its Board of Directors. Dr. Venturi is currently Group CEO of Sintetica SA, a Swiss based multinational pharmaceutical company, and he brings deep expertise in precision medicine, notably as former Senior VP at Roche and Foundation Medicine.
Dr. Brian Hashemi, Executive Chairman of Novigenix said:
“We are delighted to welcome Dr. Venturi to the Board of Novigenix as we expand our biopharma partnerships, and application of ImmunoTranscriptomic precision oncology solutions in drug development and clinical utility programs. Miro’s tremendous expertise in development of novel biomarkers brings a valuable perspective in creating value along the patient journey, and we look forward to his contribution as we scale up delivery of unique biopharma solutions to improve patient outcomes”
Dr. Miro Venturi, former Senior VP, Global Head Diagnostics Biomarkers & Personalized Healthcare at Roche, and Senior VP, Head Biopharma at Foundation Medicine said:
“Novigenix has already demonstrated the value of its ImmunoTranscriptomics platform for early detection of cancer and the Team is now making great progress towards therapy response prediction and monitoring, based on data-driven immune insights. I am very much looking forward to supporting the team in delivering differentiated solutions that can significantly improve patient outcomes and clinical utility of therapeutic modalities”
About Novigenix
Novigenix is a precision medicine biotech providing a new understanding of the human host immune response to cancer and therapeutic intervention. The Company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients, leading to significant improvement in healthcare. Novigenix’s unique Immuno-Transcriptomic platform enables an accelerated identification of disease specific mRNA signatures of immune cells, which combined with machine learning and predictive algorithms provide precision solutions for detection of disease and response to therapeutic intervention. For more information visit www.novigenix.com
Contacts
Novigenix
Valentin Matillon, President and Chief Business Officer
T: +41 21 552 07 30
E: valentin.matillon@novigenix.com
For media:
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 538 16 427
E. lmelens@lifespring.nl